IBI363 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new combination therapy called IBI363 for people with advanced solid tumors that have stopped responding to standard treatments. It includes two groups: people with EGFR-mutated non-small cell lung cancer or ovarian cancer that has returned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have an advanced solid tumor that cannot be removed by surgery and has not responded to standard treatments.
- You must be in fairly good health, able to do daily activities without help (ECOG 0 or 1).
- You must have had at least one line of platinum-based chemotherapy (for ovarian cancer) or EGFR TKI treatment (for lung cancer).
- Your blood cell counts, liver, and kidney function must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.
This study tests an experimental drug called IBI363 given before surgery for people with stage II to III non-small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a new drug called IBI363 in patients with advanced gastric or gastroesophageal junction cancer who have not yet received any treatment. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
This study tests a new drug called IBI363 for people with advanced melanoma that has progressed after standard treatment. It aims to see if IBI363 can shrink tumors or slow their growth.
Hear when a new EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.